The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

Masanori Kobayashi, Asako Chiba, Hiromi Izawa, Eri Yanagida, Masato Okamoto, Shigetaka Shimodaira, Yoshikazu Yonemitsu, Yuta Shibamoto, Noboru Suzuki, Masaki Nagaya

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC). Methods. This retrospective study included 56 ROC patients who initially received standard chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August 2013. The adverse events (AEs) and clinical responses were examined. Results: No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L before vaccination were identified as significant independent factors by multivariate Cox proportional hazard analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease control rates were 36% and 15%, respectively. Conclusions: Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.

Original languageEnglish
Article number48
JournalJournal of Ovarian Research
Volume7
Issue number1
DOIs
Publication statusPublished - May 7 2014

Fingerprint

Ovarian Neoplasms
Immunotherapy
Dendritic Cells
Peptides
Vaccination
Albumins
Drug Therapy
Survival
Cell- and Tissue-Based Therapy
Nutritional Status
L-Lactate Dehydrogenase
Immunity
Retrospective Studies
Recurrence
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. / Kobayashi, Masanori; Chiba, Asako; Izawa, Hiromi; Yanagida, Eri; Okamoto, Masato; Shimodaira, Shigetaka; Yonemitsu, Yoshikazu; Shibamoto, Yuta; Suzuki, Noboru; Nagaya, Masaki.

In: Journal of Ovarian Research, Vol. 7, No. 1, 48, 07.05.2014.

Research output: Contribution to journalArticle

Kobayashi, Masanori ; Chiba, Asako ; Izawa, Hiromi ; Yanagida, Eri ; Okamoto, Masato ; Shimodaira, Shigetaka ; Yonemitsu, Yoshikazu ; Shibamoto, Yuta ; Suzuki, Noboru ; Nagaya, Masaki. / The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. In: Journal of Ovarian Research. 2014 ; Vol. 7, No. 1.
@article{cdd09e6d7799443ab734bfe8781d9bea,
title = "The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer",
abstract = "Background: Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC). Methods. This retrospective study included 56 ROC patients who initially received standard chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August 2013. The adverse events (AEs) and clinical responses were examined. Results: No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L before vaccination were identified as significant independent factors by multivariate Cox proportional hazard analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease control rates were 36{\%} and 15{\%}, respectively. Conclusions: Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.",
author = "Masanori Kobayashi and Asako Chiba and Hiromi Izawa and Eri Yanagida and Masato Okamoto and Shigetaka Shimodaira and Yoshikazu Yonemitsu and Yuta Shibamoto and Noboru Suzuki and Masaki Nagaya",
year = "2014",
month = "5",
day = "7",
doi = "10.1186/1757-2215-7-48",
language = "English",
volume = "7",
journal = "Journal of Ovarian Research",
issn = "1757-2215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

AU - Kobayashi, Masanori

AU - Chiba, Asako

AU - Izawa, Hiromi

AU - Yanagida, Eri

AU - Okamoto, Masato

AU - Shimodaira, Shigetaka

AU - Yonemitsu, Yoshikazu

AU - Shibamoto, Yuta

AU - Suzuki, Noboru

AU - Nagaya, Masaki

PY - 2014/5/7

Y1 - 2014/5/7

N2 - Background: Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC). Methods. This retrospective study included 56 ROC patients who initially received standard chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August 2013. The adverse events (AEs) and clinical responses were examined. Results: No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L before vaccination were identified as significant independent factors by multivariate Cox proportional hazard analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease control rates were 36% and 15%, respectively. Conclusions: Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.

AB - Background: Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC). Methods. This retrospective study included 56 ROC patients who initially received standard chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August 2013. The adverse events (AEs) and clinical responses were examined. Results: No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L before vaccination were identified as significant independent factors by multivariate Cox proportional hazard analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease control rates were 36% and 15%, respectively. Conclusions: Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.

UR - http://www.scopus.com/inward/record.url?scp=84900541220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900541220&partnerID=8YFLogxK

U2 - 10.1186/1757-2215-7-48

DO - 10.1186/1757-2215-7-48

M3 - Article

VL - 7

JO - Journal of Ovarian Research

JF - Journal of Ovarian Research

SN - 1757-2215

IS - 1

M1 - 48

ER -